Since Andrew had earlier described the cut as the result of a fall while climbing, it merely showed that Quito was a small place where gossip traveled fast. "I feel terrible about that," Celia said. It was a few hours later and they were having lunch with the children. "No need to," Andrew reassured her.”There was a moment when I felt like doing the same thing. But you were the one who happened to have a shoe handy. Besides, my aim isn't nearly as good as yours.”
Celia shook her head.”Don't joke about it.”
It was then that Bruce, who had been silent through the meal, spoke up and asked, "Will you get a divorce now?" His small, serious face was tightly set, reflecting worry, making it clear the question had been weighing on him for some time. Andrew was about to answer flippantly when Celia stopped him with a gesture.”Brucie," she said gently, "I promise and swear to you that as long as your father and I live, that will never happen.”
"That goes for me too," Andrew added, and their son's face lighted up in a radiant smile, as did Lisa's beside him. "I'm glad," Bruce said simply, and it seemed a fitting end to a nightmare which was past.
There were other, happier journeys the family shared during the lustrum spent by Celia with International Sales. As to Celia's career, the period proved overall successful, enhancing her reputation at Felding-Roth headquarters. She even, despite opposition within the company, managed to achieve some headway in having the labeling of Felding-Roth drugs sold in Latin America come closer to the precise standards required by law in the United States. However, as she admitted frankly to Andrew, the progress was "not much.”
"The day will come," Celia predicted, "when someone will bring this whole subject out into the open. Then, either new laws or public opinion will compel us to do what we should have been doing all along. But that time isn't yet.”
An idea whose time had come was encountered by Celia in Peru. There, a large part of the Felding-Roth sales force was composed of women. The reason, Celia learned, was not liberation; it was sales. In Peru it is considered rude to keep a woman waiting; therefore in doctors' office-, detail women were ushered into a doctor's presence quickly, ahead of male competitors who might have to wait for hours. The discovery prompted a long memorandum from Celia to Sam Hawthorne urging recruitment of more detail women on Felding-Roth's U.S. sales force for the same reason.”I remember from my own time as a detail woman," Celia wrote, "that while sometimes I had to wait to see doctors, at other times they saw me quickly, and I think it was because I was a woman, so why not use that to our advantage?" In a subsequent discussion Sam put the question: "Isn't what you're suggesting a way of advancing women for the wrong reason? That's not women's lib. That's just using women's femininity.”
"And why not?" Celia shot back.”Men have used their masculinity for centuries, often to women's disadvantage, so it's our turn now. Anyway, man or woman, we're all entitled to make the most of what we have.”
In the end, Celia's memo was taken seriously and began a process in Felding-Roth which, during the years that followed, was copied enthusiastically by other drug houses. And during all this time, beyond the pharmaceutical business, outside events marched on. The tragedy of Vietnam was taking shape and worsening, with young Americans-the cream of a generation-being slain by tiny people in black pajamas, and no one really knowing why. A rock-music cult called "Woodstock Nation" flared briefly, then burned out. In Czechoslovakia the Soviet Union brutally extinguished freedom. Dr. Martin Luther King, Jr., and Robert Kennedy were savagely assassinated. Nixon became President, Golda Meir prime minister of Israel. Jackie Kennedy married Aristotle Onassis. Eisenhower died. Kissinger went to China, Armstrong to the moon, Edward Kennedy to Chappaquiddick. Then, in February 1972, Sam Hawthorne, at age fifty-one, became president and chief executive officer of Felding-Roth. His accession to power was sudden, and occurred at a difficult, critical period in the company's history.
Sam Hawthorne, in the jargon of the times, was a Renaissance man. He had a multiplicity of interests, indoors and out, intellectual and athletic. He was at heart a scholar who, despite heavy involvement in business, managed to keep alive a lifelong, well-informed love of literature, art and music. In foreign cities, no matter how great the pressures of work Sam would somehow find time to visit bookstores, galleries and concerts. In painting he favored the Impressionists, inclining to Monet and Pissarro. In sculpture his great love was Rodin. Lilian Hawthorne once told a friend that in Paris, in the garden of the Rodin Museum, she had seen her husband stand silent for fifteen minutes contemplating "The Burghers of Calais," much of the time with tears in his eyes. In music, Sam's passion was Mozart. A proficient pianist himself, though not a brilliant one, he liked to have a piano in his hotel suite while on trips and play something from Mozart, perhaps the Sonata No. I I in A-the grave and clear Andante, the quickening Menuetto, and finally the joyous Turkish Rondo, sending his spirits soaring after a tiring day. The fact that he had a piano in what was usually a luxury suite was because he paid for such things himself. He could afford to. Sam was independently wealthy and owned a substantial amount of Felding-Roth stock, having inherited it from his mother who died when he was young.
His mother had been a Roth, and Sam was the last member of either the Felding or Roth clan to be involved in company management. Not that his family connections had made much, if any, difference to his career; they hadn't, particularly as he neared the top. What Sam had achieved was through ability and integrity, and the fact was widely recognized. At home, Sam and Lilian Hawthorne's marriage was solid and both adored Juliet, now fifteen and apparently unspoiled despite the adoration. In athletics Sam had been a long-distance runner in college and still enjoyed an tarly morning run several times a week. He was an enthusiastic and fairly successful tennis player, though the enthusiasm was stronger than his style. Sam's greatest asset on the court was a vicious volley at the net, making him a popular doubles partner. But dominating all outside interests, sporting or cerebral, was the fact that Sam Hawthorne was an Anglophile. For as long as he could remember he had loved visiting England, and felt an admiration and affinity for most things English-traditions, language, education, humor, style, the monarchy, London, the countryside, classic cars. In line with the last preference, he owned and drove to work each day a superb silver-gray Rolls-Bentley. Something else that held Sam's high opinion was British-not just English-science, and it was this conviction that prompted an original, daring proposal during the opening months of his FeldingRoth presidency. In a confidential, written submission to the board of directors he set out some stark, unpleasant facts. "In drug research and production--our raison detre--our company is in a barren, dispiriting period which has extended far beyond the 'flat spell' experienced by this industry generally. Our last major breakthrough was with Lotromycin, nearly fifteen years ago. Since then, while competitors have introduced major, successful new drugs, we have had only minor ones. Nor do we have anything startling in sight. "All this has had a depressing effect on our company's reputation and morale. Equally depressing has been the effect on finances. It is the reason we reduced our dividend last year, an action which caused the value of our stock to plummet, and it is still out of favor with investors.
"We have begun internal belt tightening, but this is not enough. In two to three years, if we fail to produce a strong, positive program for the future we will face a financial crisis of the gravest kind.”
What Sam did not say was that his predecessor as president and CEO, who had been dismissed after a confrontation with the board, had followed a top-level policy of "drift" which, in large part, had reduced Felding-Roth Pharmaceuticals to its present sorry state. Instead, and having set the stage, Sam moved on to his proposal. "I strongly and urgently recommend," he wrote, "that we create a Felding-Roth Research Institute in Britain. The institute would be headed by a topflight British scientist. It would be independent of our research activities in the United States.”